ArticleDermatology and therapy2025
Real-World Onset of Atopic Comorbidities Relative to Atopic Dermatitis in Pediatric Patients.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical profile, reported triggers, and comorbidity pattern in children and adolescents with atopic dermatitis: a cross-sectional study from Fujian, China.Frontiers in pediatrics · 2026Article
- A systemic epithelial-immune-neural framework for pediatric atopic dermatitis-allergic rhinitis comorbidity.Frontiers in immunology · 2026Article
- Interactive Effects of Genetic Susceptibility and Early-Life Tobacco Smoke Exposure on the Asthma-Eczema Complex Phenotype in Children: 6-Year Follow-Up Case-Control Study.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with atopic dermatitis (AD) have a high atopic comorbidity burden. Although traditionally seen as beginning with AD and progressing to other atopic comorbidities, the "atopic march" model does not fit all patients. This manuscript describes the onset of atopic comorbidities among children newly diagnosed with AD.
methodsThis retrospective, observational, cohort study used data from the Israeli Maccabi Healthcare Services. Patients (< 18 years) first diagnosed with AD during 2000-2019 with ≥ 12-month enrollment before and after AD diagnosis were included. Outcomes included cumulative asthma, allergic rhinitis (AR), and food allergy (FA) prevalence. Patients were grouped by age at AD diagnosis (< 3, 3-5, 6-11, and 12-17 years).
resultsOf 177,081 included patients, 60.4% were < 3 years old at AD diagnosis. The baseline asthma prevalence (at or before AD diagnosis) was lower in children aged < 3 versus ≥ 3 years at AD diagnosis (10.6% versus 26.3-28.5%). The baseline AR prevalence increased with age from 2.2% (< 3 years) to 23.2% (12-17 years), while FA decreased from 4.9% (< 3 years) to 2.1% (12-17 years). Cumulative asthma and FA prevalence increased sharply in the year following AD diagnosis among children diagnosed at < 3 years old. The cumulative ≥ 1 asthma/AR/FA prevalence increased to approximately 50% by 10 years after AD diagnosis.
conclusionsChildren diagnosed with AD at an early age mostly acquire atopic comorbidities within 1 year following AD diagnosis, while children diagnosed later have often already developed them. Eventually, all pediatric patients with AD display a similar, significant burden of atopic multimorbidity. Graphical abstract available for this article.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.